Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q2 2026 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2025 Net Income-$18.92M-$18.92MN/M vs Q2 2025 EPS Diluted-$1.07-$1.07N/M vs Q2 2025 Operating Income-$20,110,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$17,030,000N/M ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end